Abstract: INTRODUCTION: Treatment of metastatic hormone sensitive prostate cancer (mHSPC) has traditionally included combination therapy of androgen deprivation therapy (ADT) with …
Abstract: INTRODUCTION: Testicular cancer (TC) is the most common malignancy among young males and is associated with cure rates over 95%. However, the long-term health …
Abstract: BACKGROUND: Abiraterone and enzalutamide are second generation androgen receptor pathway inhibitors (ARPIs) used to treat advanced or metastatic prostate cancer. Without …
Abstract: Introduction: The role of local definitive therapy in addition to systemic treatment in clinically positive regional lymph node (cN + ) bladder cancer is yet to be …